Abstract The crystal structure of 8-((dimethylamino)methyl)-1-(3-(dimethylamino)propyl)- 1,7,8,9-tetrahydrochromeno [5,6-d]imidazol-2-amine (1), an inhibitor of the hepatitis C virus internal ribosome entry site, is described and compared to the structure of the compound in complex with the viral RNA target. Compound 1 crystallized by pentane vapor diffusion into dichloroethane solution. It crystallized in the monoclinic system, P2 1 /c space group with unit cell parameters a = 15.7950 (5) 
Introduction
Compounds containing the 2-aminobenzimidazole scaffold have been shown to inhibit the hepatitis C virus (HCV) by binding to the internal ribosome entry site (IRES) RNA and inducing a conformational change which selectively blocks viral protein synthesis [1] . The title compound 1, which is a potent inhibitor of HCV translation, has previously been used for co-crystallization with the viral RNA target and structure determination by X-ray crystallography [2] . The benzimidazole inhibitor 1 was synthesized over 9 steps from 2-chloro-6-hydroxybenzaldehyde (2) following a recently established route (Scheme 1) [3] . The title compound 1 was obtained as a racemic mixture whose crystal structure is described here and compared to the structure of the inhibitor in complex with the viral RNA target.
Experimental
The Title Compound 1 was Synthesized Following a Recently Established Route [3] X-ray Crystallography X-ray diffraction data of the title compound were collected on a Bruker Kappa diffractometer equipped with an APEX CCD II area detector using graphite-monochromated Cu K a radiation (k = 1.54178 Å ). A colorless plate (0.2 9 0.3 9 0.5 mm) was mounted on a cryoloop with paratone oil. Data were collected in a nitrogen gas stream at 173(2) K using phi and omega scans. The data were integrated using the Bruker SAINT [4] software and scaled using the SADABS [5] program. Solution by direct methods (SHELXS) [6] produced complete phasing models consistent with the proposed structures which were refined by least square methods on F 2 using the SHELXL-97 [6] program package. The refinement was continued until the maximum shift/e.s.d was 0.000. The final difference map was featureless with maximum and minimum electron densities at 0.192 and -0.167 eÅ -3 . The crystal data, intensity collection conditions and refinement parameters are presented in Table 1 . All non-hydrogen atoms were refined anisotropically by full-matrix least-squares. Selected bond lengths and bond angles are given in Tables 2 and  3 . Hydrogen atoms H(14A) and H(14B) were allowed to refine freely. All other H atoms were located geometrically, with C-H = 0.95-1.0 Å and treated using a riding model, with isotropic U set to 1.2 times the isotropic equivalent of that of the attached parent atom. For the methyl group, the C-C-H angles and C-H distances were fixed, but the CH 3 group was allowed to rotate about the C-CH 3 bond. 
Results and Discussion
Benzimidazole Inhibitor Crystal Structure
Depending on the crystallization conditions, compound 1 crystallized either in the monoclinic P2 1 /c space group with one molecule in the asymmetric unit or in the orthorhombic Pna2 1 space group with two molecules in the asymmetric unit. An ORTEP drawing of the asymmetric unit with atom numbering scheme is shown in Fig. 1 . The core bicyclic ring system of compound 1 is essentially planar with the mean deviation from the plane for all non-hydrogen atoms of 0.0124 Å . The pyran ring in 1 is structurally disordered with a 3:1 ratio in favor of the R-enantiomer. As a consequence of this disorder, the dimethylamine alkyl chain on the pyran ring is also disordered. Hydrogen atoms H(14A) and H(14B) were easily located from the electron density map. The dimethylamine-propyl chain folds in such a conformation that it allows for the formation of an intramolecular hydrogen bond of N (19) (Table 4) correspond to the key interactions that occur when 1 binds to the Hoogsteen edge of a guanine residue in the viral RNA target (see next section) [2] . The dimers are positioned within a plane as shown in Fig. 2 . Planes stack along the c-axis as shown on Fig. 3 . Crystals of compound 1 in the orthorhombic crystal system were obtained by slow evaporation from a methanol solution. Compound 1 crystallized in the Pna2 1 space group with a racemate of two molecules (R-and S-enantiomer) in the asymmetric unit. While the S-form (1S) is more planar (mean deviation from the plane is 0.0084 Å ), the R-form (1R) is less planar (mean deviation from the plane is 0.0193 Å ) then the enantiomers of 1 in the P2 1 /c space group. 1R and 1S exhibit the same hydrogen bonding pattern as 1 and form 1R-1S dimeric units. These dimers form a zigzag pattern along the c-axis.
Comparison of the Crystal Structure of the Small Molecule Free and in Complex with the Viral RNA Target
Packing interactions of compound 1 in the crystal lattice are found analogously in key interactions of the inhibitor with its viral RNA target (Fig. 4) . Hydrogen bonds between the (2) 122.1 (2) amino-imidazole moiety in dimers of both enantiomers of 1 in the small molecule crystal correspond to bonds formed by docking of 1 at the Hoogsteen edge of G110 in the HCV IRES. In the RNA complex, the benzimidazole 1 partially intercalates between two nucleotide bases, G52 and A53. Similarly, the compound 1 is stacking in a co-planar fashion between neighboring molecules in the small molecule crystal lattice. Interestingly, the conformation of both exocyclic dimethylamino alkyl substituents of 1 is similar both in the small molecule crystal and the RNA complex, suggesting that binding to the viral target requires little conformational adaptation of the ligand.
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